Stay updated on Nivolumab + HF10 for Resectable Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.

Latest updates to the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.6.4 was added and Revision: v3.6.3 was removed, updating the page's version label.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe page's revision tag was updated from v3.6.2 to v3.6.3. This reflects an internal update to the page's revision history and does not affect the visible trial information.SummaryDifference0.1%

- Check43 days agoChange DetectedThe page revision identifier was updated from v3.6.0 to v3.6.2, indicating a minor update to the study record. No substantive content changes are indicated.SummaryDifference0.1%

- Check57 days agoChange DetectedThe study page now indicates that recruitment is closed, reflecting that no further participants will be enrolled. This helps users understand that enrollment has ended and to adjust expectations accordingly.SummaryDifference0.8%

- Check64 days agoChange DetectedThe page now displays Revision: v3.5.5, replacing the previous v3.5.4, indicating a maintenance update to the page. This change does not modify the study details or other substantive content on the page.SummaryDifference0.1%

- Check71 days agoChange Detected- The related topics section no longer lists Melanoma and the MedlinePlus Genetics entry.SummaryDifference0.2%

Stay in the know with updates to Nivolumab + HF10 for Resectable Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.